TY - JOUR
T1 - Prognostic implications of human papillomavirus status and p16 expression in laryngeal squamous cell carcinoma
AU - Zhu, Yingying
AU - Xia, Xin
AU - Gross, Neil
AU - Dahlstrom, Kristina R.
AU - Gao, Liming
AU - Liang, Zhiyong
AU - Gao, Zhiqiang
AU - Wei, Peng
AU - Liu, Chuan
AU - Li, Guojun
AU - Li, Yuncheng
AU - Chen, Xingming
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Background: The purpose of this study was to investigate significance of HPV16 DNA/p16 for survival of patients with laryngeal squamous cell carcinoma (LSCC). Methods: HPV16 DNA and p16 status in 812 LSCC patients were determined. The survival was performed using Kaplan-Meier estimates and Cox model. Results: Compared with HPV negativity, adjusted HRs for HPV16 positivity were 0.57, 95% CI, 0.38 to 0.87; 0.60, 0.40 to 0.88; and 0.65, 0.46 to 0.94 for disease-specific survival (DSS), recurrence-free survival (RFS), and overall survival (OS), respectively. Additionally, for p16 expression, aHRs were 0.68, 95% CI, 0.48 to 0.96; 0.72, 0.52 to 0.98; and 0.73, 0.54 to 0.99 for DSS, RFS, and OS, respectively. Finally, for combined analysis, patients with both HPV16-positivity/p16-positivity had much better prognosis than those with either negativity. Such above survivals are more significantly better in never smokers. Conclusion: Our findings suggest that HPV16/p16 may affect survival outcomes of LSCC patients, particularly in never smokers.
AB - Background: The purpose of this study was to investigate significance of HPV16 DNA/p16 for survival of patients with laryngeal squamous cell carcinoma (LSCC). Methods: HPV16 DNA and p16 status in 812 LSCC patients were determined. The survival was performed using Kaplan-Meier estimates and Cox model. Results: Compared with HPV negativity, adjusted HRs for HPV16 positivity were 0.57, 95% CI, 0.38 to 0.87; 0.60, 0.40 to 0.88; and 0.65, 0.46 to 0.94 for disease-specific survival (DSS), recurrence-free survival (RFS), and overall survival (OS), respectively. Additionally, for p16 expression, aHRs were 0.68, 95% CI, 0.48 to 0.96; 0.72, 0.52 to 0.98; and 0.73, 0.54 to 0.99 for DSS, RFS, and OS, respectively. Finally, for combined analysis, patients with both HPV16-positivity/p16-positivity had much better prognosis than those with either negativity. Such above survivals are more significantly better in never smokers. Conclusion: Our findings suggest that HPV16/p16 may affect survival outcomes of LSCC patients, particularly in never smokers.
KW - human papillomavirus
KW - laryngeal neoplasms
KW - p16
KW - prognosis
KW - squamous cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85073997991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073997991&partnerID=8YFLogxK
U2 - 10.1002/hed.25961
DO - 10.1002/hed.25961
M3 - Article
C2 - 31566825
AN - SCOPUS:85073997991
SN - 1043-3074
VL - 41
SP - 4151
EP - 4163
JO - Head and Neck
JF - Head and Neck
IS - 12
ER -